Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma

[1]  A. Halpern,et al.  Melanoma, version 4.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[4]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[5]  Jared C Malke,et al.  Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma , 2014, The Journal of investigative dermatology.

[6]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[7]  F. Waldman,et al.  Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. , 2013, The Journal of molecular diagnostics : JMD.

[8]  F. Hodi,et al.  Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. , 2013, The oncologist.

[9]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[10]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[11]  M. Weinstein,et al.  Guidelines for Pharmacoeconomic Studies , 1997, PharmacoEconomics.

[12]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[13]  V. Sondak,et al.  Chemotherapy for metastatic melanoma , 2007, Cancer.

[14]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Derek Y. Chiang,et al.  Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma , 2014, Pigment cell & melanoma research.

[16]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[17]  M C Weinstein,et al.  Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.

[18]  S. O'toole,et al.  BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.

[19]  W. Sung,et al.  Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas , 2014, PloS one.

[20]  T. Delea,et al.  Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada , 2015, PharmacoEconomics.

[21]  Alexander J. Lazar,et al.  Beyond BRAF V600 , 2015 .

[22]  J. Schellens,et al.  The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. , 2013, European journal of cancer.

[23]  G. Long,et al.  Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. , 2013, European journal of cancer.

[24]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[25]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[26]  William Pao,et al.  Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. , 2014, The oncologist.

[27]  M. Atkins,et al.  Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis , 2013, Journal of medical economics.

[28]  A. Levy,et al.  Societal preference values for advanced melanoma health states in the United Kingdom and Australia , 2009, British Journal of Cancer.

[29]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.